QT interval prolongation in people treated with bedaquiline for drug-resistant tuberculosis

Authors

  • Mohammad Zannatul Rayhan Department of Respiratory Medicine, Chest Disease Clinic, Rajshahi, Bangladesh
  • M. Rokib Sadi Department of Medicine, Rajshahi Medical College, Rajshahi, Bangladesh
  • Prosad Kumer Sarker Department of Interventional Neurology, Rajshahi Medical College, Rajshahi, Bangladesh
  • M. Asif Hossain Department of Medicine, Rajshahi Medical College, Rajshahi, Bangladesh
  • Most Mehenaz Alam Department of Dermatology, Barind Medical College and Hospital, Rajshahi, Bangladesh

DOI:

https://doi.org/10.18203/2320-6012.ijrms20241223

Keywords:

Arrhythmias, Bedaquiline, QT interval prolongation

Abstract

Background: Bedaquiline (BDQ) is indeed recommended for treating multidrug-resistant tuberculosis (MDR-TB). However, it's essential to monitor patients receiving bedaquiline therapy closely because it has been associated with prolongation of the QTc interval. This study aimed to assess the association of bedaquiline to QT interval prolongation in DR-TB patients.

Methods: This was an observational longitudinal study conducted in the Department of Respiratory Medicine in Chest Disease Hospital, Rajshahi, from August 2020 to February 2023.  A total of 44 MDR-TB patients were included in the study. Data analyses were done by using Statistical Package for Social Sciences (SPSS) version 25.0.

Results: Out of 44 patients the majority 30(68.2%) patients belonged to age >40 years with a mean age of 49.3±15.6 years, and all patients were male. All MDR patients were detected by sputum Gene-Xpert, 44 (100%), and sputum for AFB culture was done in all patients, 44 (100%). QT level and QT changes were statistically significant for baseline and 24 weeks. Only one patient died in 2 weeks of follow-up (Table 3). Changes of QT >60 ms was found in 6 (13.6%) and ≤60 ms was 38 (86.4%). Age, sex, marital status, residence, educational status, occupational status, monthly income, chief complaints, co-morbidities, and using drug-causing QT prolongation were not statistically significant (p>0.05).

Conclusions: Prolonged QT interval is in DR-TB patients who receive treatment using the bedaquiline regimen. We observed that with a moderate prolongation of QTc, there were no arrhythmias recorded and 1 death occurred due to acute MI.

References

Ndjeka N, Schnippel K, Master I, Meintjes G, Maartens G, Romero R, et al. Euro Respirat J. 2018;52(6):1801528.

Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, et al. An individual patient data meta-analysis of 9,153 patients. PLoS Med. 2012;9(8):e1001300.

Isralls S, Baisley K, Ngam E, Grant AD, Millard J. QT interval prolongation in people treated with bedaquiline for drug-resistant tuberculosis under programmatic conditions: a retrospective cohort study. Open Infect Dis. 2021;8:1-10.

Katraka S, Lowenthala P, Shenc R, Truea L, Henrya L, Barry P. Bedaquiline for multidrug-resistant tuberculosis and QTc prolongation in California. J Cli Tubercul O Mycobacter Dis. 2021;23(2021):100216.

Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Eng J Medi. 2014;371(8):723-32.

Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL, et al. Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA clinical practice guideline. Am J Respir Criti Care Medi. 2019;200(10):e93-142.

WHO. WHO consolidated guidelines on drug-resistant tuberculosis treatment, 2019. Available at: https://www.who.int/publications/i/item/9789241550529. Accessed on 08 February 2024.

National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Division of Tuberculosis Elimination. TB Elimination. Treatment of Multidrug-Resistant Tuberculosis: Bedaquiline. Available at: https://www.cdc.gov/tb/publications/factsheets/treatment/Multidrug-Resistant_Tuberculosis_Bedaquiline.pdf. Accessed on 08 February 2024.

Primadana V, Yovi I, Estiningsih DS. Bedaquiline Correlation to QT Interval Prolongation in DR-TB Patients. J Respi. 2022;08(03):140-6.

Pontali E, Sotgiu G, Tiberi S, D'Ambrosio L, Centis R, Migliori GB. Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence. Euro Respirat J. 2017;50(5):1701462.

Postema P, Wilde A. The Measurement of the QT Interval. Curr Cardiol Rev. 2014;10(3):287-94.

Guo H, Courbon GM, Bueler SA, Mai J, Liu J, Rubinstein JL. Structure of mycobacterial ATP synthase bound to the tuberculosis drug bedaquiline. Nature. 2021;589(7840):143-7.

Lakshmanan M, Xavier A. Bedaquiline - the first atp synthase inhibitor against multi drug resistant tuberculosis. J Young Pharm. 2013;5:112-5.

Brust JC, Gandhi NR, Wasserman S, Maartens G, Omar SV, Ismail NA, et al. Effectiveness and cardiac safety of bedaquiline-based therapy for drug-resistant tuberculosis: a prospective cohort study. Clin Infect Dis. 2021;73(11):2083-92.

Darmayani GAAPS, Ascobat P, Instiaty, Sugiri YJR, Sawitri N. Bedaquiline effect on QT interval of drugs-resistant tuberculosis patients: real world data. Acta Med Indones - Indones J Intern Med. 2022;54(3): 389-95.

Cunha JP. Sirturo, 2021. Available at: https://www.rxlist.com/sirturo-drug.htm. Accessed on 08 February 2024.

Downloads

Published

2024-04-30

How to Cite

Rayhan, M. Z., Sadi, M. R., Sarker, P. K., Hossain, M. A., & Alam, M. M. (2024). QT interval prolongation in people treated with bedaquiline for drug-resistant tuberculosis. International Journal of Research in Medical Sciences, 12(5), 1430–1437. https://doi.org/10.18203/2320-6012.ijrms20241223

Issue

Section

Original Research Articles